^
Association details:
| Biomarker: | MYC overexpression + BCL2 overexpression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Regimen: | (vincristine + Rituxan (rituximab) + doxorubicin hydrochloride + prednisone + cyclophosphamide + etoposide IV) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
DOSE-ADJUSTED EPOCH AND RITUXIMAB (DA-EPOCH-R) FOR THE TREATMENT OF DUAL EXPRESSOR AND DOUBLE HIT DIFFUSE LARGE B-CELL LYMPHOMA: A RETROSPECTIVE, MULTICENTER ITALIAN STUDY
Published date:
06/12/2020
Excerpt:
Diffuse Large B-Cell Lymphoma (DLBCL) is a heterogeneous disease with as many as one-third of cases overexpressing MYC and BCL2 proteins (Dual Expressor Lymphoma, DEL)...A series of 123 consecutive pts with biopsy proven diagnosis of DEL (cut-off values of ≥40% for MYC and ≥50% for BCL2), DEL-Single Hit (DEL-SH, i.e., with a rearrangement of either MYC or BCL-2), or DEL-DH were treated with 6 cycles of DA-EPOCH-R....DA-EPOCH-R is an effective treatment for DEL and DEL-SH whereas inferior results were observed in the DEL-DH subgroup.
